Scholarlink

Background <p>Oxaliplatin (OXA) has become a key chemotherapeutic agent in the treatment of esophageal squamous cell carcinoma (ESCC). Toll-like receptor 4 (TLR4) is frequently upregulated in OXA-treated tumors, yet its role in regulating OXA sensitivity in ESCC remains unclear. This study suggests that TLR4 acts as a critical regulator of OXA responsiveness through dual modulation of NF-κB p65-driven inflammation and HIF-1α/GLUT1-mediated glycolysis.</p> Methods <p>Using ESCC cell lines and a 4-nitroquinoline 1-oxide (4-NQO)-induced murine ESCC model, we demonstrated that OXA upregulates TLR4 and its adaptor protein MYD88, thereby stimulating inflammatory cytokine production and activating glycolytic enzymes. Pharmacological inhibition or shRNA-mediated knockdown of TLR4 significantly enhanced the suppressive effects of OXA on ESCC proliferation, migration, and invasion in vitro.</p> Results <p>TLR4 knockout markedly improved the efficacy of OXA in vivo, reducing tumor burden while simultaneously downregulating key inflammatory mediators and glycolytic markers.</p> Conclusions <p>These findings indicate that TLR4 inhibition enhances OXA’s chemotherapeutic effects by attenuating both inflammation and glycolytic metabolism. Our results support TLR4 signaling as a pivotal modulator of OXA sensitivity in ESCC and propose TLR4 targeting as a promising strategy for improving OXA-based chemotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inhibition of TLR4 enhances oxaliplatin chemotherapy sensitivity in esophageal squamous cell carcinoma by suppressing inflammation and glycolysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月10日

查看全文
  • Ziqi Zhu,
  • Meng Zhang,
  • Zequn Di,
  • Xin Tao,
  • Yaohui Dai,
  • Zhiqiang Zhan,
  • Hongping Chen

摘要

Background

Oxaliplatin (OXA) has become a key chemotherapeutic agent in the treatment of esophageal squamous cell carcinoma (ESCC). Toll-like receptor 4 (TLR4) is frequently upregulated in OXA-treated tumors, yet its role in regulating OXA sensitivity in ESCC remains unclear. This study suggests that TLR4 acts as a critical regulator of OXA responsiveness through dual modulation of NF-κB p65-driven inflammation and HIF-1α/GLUT1-mediated glycolysis.

Methods

Using ESCC cell lines and a 4-nitroquinoline 1-oxide (4-NQO)-induced murine ESCC model, we demonstrated that OXA upregulates TLR4 and its adaptor protein MYD88, thereby stimulating inflammatory cytokine production and activating glycolytic enzymes. Pharmacological inhibition or shRNA-mediated knockdown of TLR4 significantly enhanced the suppressive effects of OXA on ESCC proliferation, migration, and invasion in vitro.

Results

TLR4 knockout markedly improved the efficacy of OXA in vivo, reducing tumor burden while simultaneously downregulating key inflammatory mediators and glycolytic markers.

Conclusions

These findings indicate that TLR4 inhibition enhances OXA’s chemotherapeutic effects by attenuating both inflammation and glycolytic metabolism. Our results support TLR4 signaling as a pivotal modulator of OXA sensitivity in ESCC and propose TLR4 targeting as a promising strategy for improving OXA-based chemotherapy.